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Abstract
The ability of a bis-amino mitoxantrone anticancer drug (named WEHI-150) to form covalent adducts with DNA, after activation by formaldehyde, has been studied by electrospray ionisation mass spectrometry and HPLC. Mass spectrometry results showed that WEHI-150 could form covalent adducts with d(ACGCGCGT) 2 that contained one, two or three covalent links to the octanucleotide, whereas the control drugs (daunorubicin and the anthracenediones mitoxantrone and pixantrone) only formed adducts with one covalent link to the octanucleotide. HPLC was used to examine the extent of covalent bond formation of WEHI-150 with d(CGCGCG) 2 and d(CG 5Me CGCG) 2 . Incubation of WEHI-150 with d(CG 5Me CGCG) 2 in the presence of formaldehyde resulted in the formation of significantly greater amounts of covalent adducts than was observed with d(CGCGCG) 2 . In order to understand the observed increase of covalent adducts with d(CG 5Me CGCG) 2 , an NMR study of the reversible interaction of WEHI-150 at both CpG and 5Me CpG sites was undertaken.
Intermolecular NOEs were observed in the NOESY spectra of d(ACGGCCGT) 2 with added WEHI-150 that indicated that the drug selectively intercalated at the CpG sites and from the major groove. In particular, NOEs were observed from the WEHI-150 H2,3 protons to the H1' protons of G 3 and G 7 and from the H6,7 protons to the H5 protons of C 2 and C 6 . By contrast, intermolecular NOEs were observed between the WEHI-150 H2,3 protons to the H2" proton of the 5Me C 3 in d(CG 5Me CGCG) 2 , and between the drug aliphatic protons and the H1' proton of G 4 . This demonstrated that WEHI-150 preferentially intercalates at 5Me CpG sites, compared to CpG sequences, and predominantly via the minor groove at the 5Me CpG site. The results of this study demonstrate that WEHI-150 is likely to form interstrand DNA cross-links, upon activation by formaldehyde, and consequently exhibit greater cytotoxicity than other current anthracenedione drugs.
Introduction
Anthracyclines (e.g. daunorubicin, see Figure 1 ) are an important class of anticancer agents that continue to play a significant role in the treatment of cancer. [1] [2] [3] However, their clinical use is limited by their cardiotoxicity. 4 This dose-limiting toxicity has promoted the search for new anthracenedione, and aza-anthracenedione derivatives, with comparable cytotoxicity but lower cardiotoxicity. Mitoxantrone and pixantrone (see Figure 1 ) are two examples of synthetic second generation anthracycline derivatives that exhibit significantly lower cardiotoxicity but maintain potent anticancer activity. [5] [6] [7] [8] Similar to the parent anthracyclines, the anthracenedione analogues can bind DNA by intercalation between the base pairs and thereby induce their cytotoxic effect through the impairment of topoisomerase II. [9] [10] [11] In addition, in an attempt to develop an alternative pathway to anticancer activity, anthracenediones have also been used to target G-quadruplex DNA structures. 12, 13 Recently, it has been demonstrated that daunorubicin, mitoxantrone and pixantrone can form drug-DNA covalent adducts at the N-2 amino groups of guanine nucleotides after activation by formaldehyde. [14] [15] [16] As the anthracenedione analogues are more cytotoxic to cells and solid tumours that produce higher levels of formaldehyde, it has been proposed that covalent bond formation is an important contributing mechanism to the anticancer properties of these compounds. Additionally, it has been established that the combination of an anthracycline drug and a formaldehyde-releasing pro-drug is synergistic in cancer cell lines, and leads to apoptosis independently of topoisomerase II-mediated damage. [17] [18] [19] Daunorubicin can only form one formaldehyde-mediated covalent bond with DNA (a N-CH 2 -N link), whereas, mitoxantrone and pixantrone can potentially form two covalent bonds, as they each contain two potentially reactive amine groups. Mitoxantrone-DNA adducts have a half-life of 50 minutes and appear to be formed between the secondary amine of one side chain and the N-2 of guanine at a CpG sequence. 20 The more recently synthesised anthracenedione pixantrone forms DNA adducts 10-to 100-fold more efficiently at CpG sites 5 than mitoxantrone and while the pixantrone-DNA adducts are still labile, they are more stable than those formed by mitoxantrone. 21 Previously, Phillips, Cutts and co-workers have also
shown that pixantrone and mitoxantrone form 2-5 fold more covalent adducts at 5'-CpG sequences when the cytosine is methylated at the C-5 position. 22 The cytosine residue in CpG sequences (found disproportionately in regulatory promoter regions) is often methylated, with methylation typically occurring after DNA replication. A bis-amino mitoxantrone analogue, named herein WEHI-150 (see Figure 1) , was synthesised in an attempt to develop anthracenedione analogues that are more reactive with DNA than mitoxantrone and pixantrone, but are also more likely to form covalent cross-links between the two DNA strands, through the formation of an adduct with a covalent bond to a guanine residue on each strand of the duplex. 24, 25 Solutions were left to equilibrate for one hour, then formaldehyde was added to the DNAdrug mixture to obtain a formaldehyde concentration of 2 mM. Samples were incubated at room temperature (21 °C) for six hours and then 10 µL of the mixture was taken and diluted just prior to ESI-MS analysis with 70 µL of 100 mM ammonium acetate and immediately analysed.
Mass spectrometry
All drug-DNA complexes were analysed under the same instrumental conditions using a Waters Q-Tof Ultima™ ESI mass spectrometer equipped with a Z-spray ionisation source and a quadrupole mass analyser with a m/z range of 32,000. Samples were injected into the mass spectrometer at a flow rate of 20 µL/min using a Harvard Model 22 syringe pump (Natick, MA, USA). All spectra were acquired using a MCP potential of 1850V, Rf lens energy of 70V, capillary voltage of 2.50 kV and sampling and extraction cone voltages were 70V and 4 V, respectively. The source temperature was 80 °C and the desolvation gas flow rate was 300
L/h at a temperature of 120 °C. All spectra were acquired in negative ion mode over the range m/z 500-4000 and typically 30 acquisitions were combined to obtain a representative spectrum. Each spectrum was then background subtracted using a polynomial order of 2 with 20% below curve, then smoothed using the MassLynx software, where 10 channels were smoothed twice. Prior to analysis the instrument was externally calibrated with a solution of 1 mg/mL caesium iodide (CsI) over the m/z acquisition range.
Sample preparation for HPLC
Oligonucleotides solutions (20 µΜ) were incubated with WEHI-150 (40 µΜ) and formaldehyde (2 mM) in 100 mM ammonium acetate pH 6.8 at 37 °C for 10 hours, then the un-reacted (including the reversibly bound) WEHI-150 was removed by phenol/chloroform extraction and the DNA precipitated by the addition of absolute ethanol. The WEHI-150-DNA adducts, a blue precipitate, were dissolved in 100 mM ammonium acetate pH 6.8 prior to injection into the HPLC. 
Sample preparation for NMR
Oligonucleotides were purified from minor impurities by passing them through a C18 SepPak cartridge and then converted to the sodium salt using a CM-Sephadex C-25 ion exchange resin column, as previously described. 30 The oligonucleotide was dissolved in 650 µL of phosphate buffer (pH 7.0), containing 20 mM NaCl and 1 mM Na 2 H 2 EDTA, and the solution was freeze-dried. 
NMR Spectroscopy
NMR experiments were recorded at 400 MHz for the 1 H nuclei using a Varian Unityplus-400 spectrometer at 25 °C unless otherwise stated and the data processed using the Agilent software Vnmrj 2.2C. Chemical shift values were referenced to HDO at 4.78 ppm relative to 2,2-dimethylsilapentane-5-sulfonic acid. One-and two-dimensional spectra were recorded in 99.9% D 2 O for the non-exchangeable protons whereas for the exchangeable protons, spectra were recorded in 90% H 2 O/10% D 2 O using the WET solvent suppression technique. Phasesensitive NOESY spectra were acquired using the method of States et al., 31 with 2048 data points in t 2 and 256 in t 1 values with pulse repetition delay of 1.7 s for mixing time ranging of 100 and 300 ms. DQFCOSY spectra were recorded using the same t 2, t 1 and pulse repetition delay as stated above.
Molecular modelling
Molecular modelling was performed using HyperChem 7.5 software. Double helix B type oligonucleotide was generated from the nucleic acid database and energy restraints were added to preserve the hydrogen bonding between base pairs expected of duplex DNA during the optimisation procedure, which were conducted in vacuo using the Amber 99 force field and a Polak-Ribiere conjugant-gradient algorithm with 5 x 10 -5 kcal/(Å mol) convergence criteria.
The point charges of WEHI-150 were determined from semi-empirical calculations using the AM1 program. The WEHI-150 complex point charges resulting from different AM1 calculations appeared to vary only slightly with the conformation. Therefore, the point charges resulting from an optimised confirmation were used to approximate the charges for the subsequent molecular modelling AMBER optimisations with the DNA oligonucleotide.
The compound was manually inserted into the free DNA model to reflect the intermolecular NOEs observed with DNA protons. Energy restraints were applied to preserve the observed intermolecular NOEs and base pair hydrogen bonds during the subsequent interactive optimization using AMBER and then the restraints were removed to confirm the resulting structure was an energy minimised structure.
Results

Mass spectrometry analysis of covalent binding
Mass spectrometry was used to identify drug-oligonucleotide complexes, both reversibly bound and covalent adducts, for WEHI-150 and the control anthracenedione drugs daunorubicin, mitoxantrone and pixantrone. Preliminary experiments indicated that under the conditions used the hexanucleotide sequence d(CGCGCG) 2 was not stable in the gas phase and mostly separated into its single strands, with only small amounts of the free and drugbound duplex being observed. Consequently, to increase duplex stability and the intensity of the observed drug-DNA adducts the octanucleotide d(ACGCGCGT) 2 Similar results were observed for pixantrone, although the proportion of the covalent adduct was significantly greater. Interestingly, the profile for WEHI-150 was different to that of the other drugs. Although not to the same degree as observed with daunorubicin, the proportion of covalently bound oligonucleotide adducts was greater than that of the reversibly bound WEHI-150. Furthermore, adducts with one, two and even three covalent links to the oligonucleotide were observed. 
Assignment of free WEHI-150
The aromatic protons in the 1 H NMR spectrum of WEHI-150 were assigned using standard one-dimensional COSY and NOESY NMR experiments and by comparison with the previously reported assignments for mitoxantrone and pixantrone. 28, 32 The H6,7 protons were assigned by the observation of a strong NOE to the Ha protons and weak NOEs to the Hb, Hc and Hd protons.
WEHI-150 binding to d(ACGGCCGT) 2
The resonances in the 1 H NMR spectra of the free and WEHI-150 bound oligonucleotide were assigned by standard techniques. [33] [34] [35] Consistent with many NMR studies of oligonucleotides, [33] [34] [35] [36] the analysis of short mixing-time NOESY and DQFCOSY spectra indicated that the octanucleotide adopted a B-type conformation in the aqueous buffer. NOESY spectra were recorded to obtain a detailed picture of the WEHI-150-oligonucleotide binding. Strong intermolecular NOEs were observed from the WEHI-150 H2,3 to the H1' protons of G 3 and G 7 and from the H6,7 protons to the H5 protons of C 2 and C 6 (see Figure 6 ). In addition, weak NOEs were also observed from the H6,7 protons of the WEHI-150 to the H6 protons of C 2 and C 6 . These NOEs indicate that WEHI-150 preferentially binds at the CpG sites of the oligonucleotide as expected. Furthermore, NOEs between the ethylene side chain protons of WEHI-150 and the major groove protons of the C 2 and C 6 were also observed. Taken together, the observed pattern of intermolecular NOEs indicates that WEHI-150 intercalates at CpG sites from the major groove. protons of the oligonucleotide to the WEHI-150 H6,7 and H2,3 respectively.
WEHI-150 binding to d(CG 5Me CGCG) 2
The addition of WEHI-150 to d(CG 5Me CGCG) 2 induced an upfield shift for the G 4 imino resonance (see Figure 7) , suggesting that WEHI-150 bound at the 5Me CpG site. Significant upfield shifts (0.59 to 0.70 ppm, see Table 3 observed (see Table 4 and Figure 8 ), suggesting there were at least two binding modes in slow exchange. 
Discussion
Anthracenedione compounds can bind DNA by intercalation and thereby exert anticancer activity through the impairment of topoisomerase II. 9, 10 However, it has also been proposed that anthracenedione drugs containing side chain amine groups can induce apoptosis in cancer cells through formation of a covalent adduct with the N-2 amino group of a guanine residue at CpG sites after activation by formaldehyde. [14] [15] [16] The results of this study confirm that daunorubicin, mitoxantrone and pixantrone can form covalent adducts with duplex DNA.
WEHI-150 was synthesised in an attempt to develop anthracenedione analogues that can form covalent cross-links between the two DNA strands, through the formation of covalent bonds to a guanine residue on each strand of the duplex. The results from this study indicate that Although pixantrone forms more covalent adducts at 5Me CpG sites than at CpG sites, previous NMR studies have established that pixantrone predominantly intercalates from the major groove at both 5Me CpG sites and CpG sites. 28 However, some minor groove binding was observed. 28 Consequently, it is possible that the additional DNA adducts formed by pixantrone at 5Me CpG sites could be due to the increased nucleophilicity of the guanine N-2 due to the electronic effect of the methylation of the complementary cytosine. For WEHI-150, the electronic effects of C-5 methylation may contribute to the increased adducts formed at 5Me CpG sites; however, the switching from intercalation from the major groove to the minor groove is likely to be more important. It is not clear why WEHI-150, unlike pixantrone, intercalates from the minor groove at 5Me CpG sites. Examination of molecular models suggests that there are no steric barriers to major groove intercalation at 5Me CpG sites for either pixantrone or WEHI-150. Base stacking is the main driving force for the formation of duplex DNA, 37 and the stacking between an intercalated drug and the base pairs at the binding site also provides favourable thermodynamic driving forces for the formation of the drug-DNA complex. 38 However, DNA groove-binding interactions are predominantly entropy driven, and it has been established that intercalation is enthalpically driven. 38 Consequently, it is likely that the stacking interactions of WEHI-150 are maximised for minor groove intercalation at 5Me CpG sites. In particular, the electrostatic dipole-dipole interactions between WEHI-150 and the DNA base pairs are a significant stabilising force for the intercalative binding, and play a role in determining the geometry of the binding. The anthracenedione moiety of WEHI-150 produces a different pattern of dipole moments, compared to the aza-anthracenedione pixantrone, which consequently results in a different binding geometry -minor groove intercalation for WEHI-150, and major groove intercalation for pixantrone.
Taken together, the results of this study demonstrate that WEHI-150 is likely to form interstrand DNA cross-links. Although it is yet to be established, it is possible that the interstrand cross-links formed by WEHI-150 would disrupt DNA-mediated processes to a greater degree than anthracenedione drugs that are capable of forming only one covalent bond with DNA. Furthermore, the observed reversible binding preference for 5Me CpG sites, compared to CpG sites, could also potentiate the anticancer properties of WEHI-150. Gene expression is largely affected by promoters, which often contain CpG "islands". 39 Although cancer cells generally contain hypomethylated genomes, CpG islands are hypermethylated. 39 Consequently, preferential binding in the DNA minor groove at the methylated CpG islands in promoter regions could allow for the optimal activity of WEHI-150 through the formation of covalent bonds with guanine residues after activation by formaldehyde.
In conclusion, the results of this study indicate that WEHI-150 can form interstrand cross-links with DNA after activation by formaldehyde. In addition, WEHI-150 predominantly intercalates from the DNA major groove at CpG sites, but from the minor groove at 5Me CpG sequences. As intercalation at 5Me CpG sites is preferred compared to nonmethylated sites, WEHI-150 forms considerably more covalent adducts at sequences containing 5Me CpG sites with adjacent guanine residues.
